Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rosetta Genomics's EPS (Basic) for the
six
months ended in Jun. 2017 was $-2.07.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2017 was $-7.08.
Rosetta Genomics (OTCPK:ROSGQ) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Rosetta Genomics Earnings per Share (Diluted) Related Terms
Rosetta Genomics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Rosetta Genomics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rosetta Genomics Earnings per Share (Diluted) Chart
ROSGQ vs TEAR, IDTA, ABMC: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Rosetta Genomics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rosetta Genomics PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Rosetta Genomics's PE Ratio falls into.
Rosetta Genomics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Rosetta Genomics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2016 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-7.08 mean?
Rosetta Genomics (ROSGQ) has a Earnings per Share (Diluted) of $-7.08 as of Jun. 2017. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Earnings per Share (Diluted) too high?
Rosetta Genomics' current Earnings per Share (Diluted) is $-7.08.
How does Rosetta Genomics' Earnings per Share (Diluted) compare to TEAR and IDTA?
Rosetta Genomics' Earnings per Share (Diluted) of $-7.08 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Earnings per Share (Diluted) is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.80, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Earnings per Share (Diluted) is $-7.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Earnings per Share (Diluted) of $-7.08. The current Earnings per Share (Diluted) is $-7.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Earnings per Share (Diluted) is $-7.08 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROSGQ has been successfully added to your 
